Major improvements in outcome after acute cardiac conditions have been observed in Europe over recent decades. The introduction of modern reperfusion therapy with thrombolysis or preferable primary percutaneous coronary intervention (PCI), as well as tailored antithrombotic therapy, have without doubt improved survival after a ST-elevation myocardial infarction (STEMI), and the focus on both pre-and in-hospital care has doubled survival in some countries after an out-of-hospital cardiac arrest (OHCA) over the same time period. Both OHCA and STEMI often require immediate help from both laypeople and health care professionals. Modern management of these conditions therefore requires a large setup involving public awareness of symptoms, immediate first aid and the dispatching of appropriate pre-hospital medical services with telemedicine, allowing for optimal referral of patients for hospital admission and acute interventions, including acute coronary angiography, PCI and targeted temperature management (TTM) in selected patients.
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Both pre-and in-hospital care of OHCA patients have changed dramatically over the last two decades, despite very few positive randomized clinical trials in this field. Even though the efficacy of each individual element of post-cardiac arrest care may be questioned, the combined bundle of care has been shown to be associated with improved outcome in observational studies. 1 In the current issues of this journal, Sulzgruber and colleagues demonstrate that 6-month survival after OHCA has improved from 28% in 1992-1998 to 43% to 2006-2012. 2 This Austrian, single-centre, observational study reports from a comprehensive database that is in excess of 4000 patients and also demonstrate improvements in bystander cardiopulmonary resuscitation and decreasing time to first medical contact, as well as increasing application of TTM and PCI, over this 20-year period. TTM and PCI were implemented in the period 1999-2005, and unlike PCI, utilization of TTM increased further from 1999-2005 to 2006-2012. Most of the increase in survival was seen from 1992-1998 to 1999-2005, indicating the importance of the combined bundle of care, rather than simply focussing on PCI and TTM.
The improvement in survival observed over the period is parallel to improvements seen in other health care systems that have implemented guideline-based treatment algorithms, even though the number of randomized trials demonstrating the efficacy of these algorithms remains low and therefore no causal relationship between individual components of care, including PCI in OHCA, can be proven. Indeed, the Austrian study demonstrated an independent, statistically significant association of guideline updates and improved survival. The actual statistical calculations performed are not described in detail, but interestingly, this association was only significant for in-hospital cardiac arrest patients, while the risk reduction was smaller and not statistically significant for OHCA patients.
Patients who are resuscitated from cardiac arrest undergo a complex series of interventions, and TTM is a part of these. TTM has been demonstrated to be safe in OHCA patients, and two midsize randomized clinical trials have demonstrated a beneficial effect of cooling to approximately 33°C for 12-24 hours, 3, 4 but the optimal targeted temperature 5 and the efficacy of the pre-hospital application of TTM immediately following return of spontaneous circulation (ROSC) 6 has been challenged. Furthermore, the evidence for TTM after OHCA has been downgraded to 'low' in the recent European Resuscitation Council (ERC) guidelines, 7 but it remains a recommended therapy.
The theory underlying the beneficial effect of lowering the body temperature after an ischaemic injury includes many pathways, and our knowledge in this field is still evolving. One of ways in which hypothermia is believed to prevent cerebral damage after an OHCA is through reducing the reperfusion injury. Thus, the therapy should probably be applied before the reperfusion begins. It seems much more feasible to cool myocardial cells after a STEMI and before reperfusion than cooling brain cells after an OHCA and before reperfusion because an immediate return of circulation is mandatory in this setting. The potential benefits of cooling in terms of reducing post-ischaemic myocardial injury is discussed in a review by Chavez et al. in the current issue of the ACCA journal. 8 Several physiological effects of cooling on the heart are known, and some may seem deleterious, with marked a reduction in heart rate and prolongation of PQ, ORS and QT intervals, as well as a reduction in cardiac output. On a cellular level, the heat shock proteins have been suggested as being part of the cellular reaction to reduced temperature, and they may possibly be one of many cellular mechanisms that may be cardioprotective. While animal models have demonstrated a benefit of reducing tissue temperature before reperfusion, none of the randomized trials performed in humans with STEMI has yet demonstrated a benefit of cooling on the primary outcome. In subgroups, particularly in patients with a short duration of symptoms and anterior infarction, a reduction in infarct size may be present, which will likely be addressed in future randomized studies. The application of cooling in STEMI patients has been proven feasible, with small delays in time to reperfusion and great safety and efficacy as found in previous studies.
We still need randomized clinical trials with clinical outcomes documenting a positive effect of cooling in awake STEMI patients before we can include TTM in our bundle of care for these patients. Regarding comatose OHCA patients, the clinical use of TTM seems reasonable, but because of the many uncertainties, this has let the ERC guidelines to conclude that the evidence grade is low for this therapy; a new large-scale clinical trial retesting the effect of TTM in comatose OHCA patients will also be welcome. Such trials are not only much wanted in TTM, but also for addressing other elements of the treatment bundle, such as goal-directed therapy (i.e. blood pressure targets and sedation strategies), fluid management or the development of pharmacological substances that may have neuro-and cardio-protective effects that ameliorate the devastating effects of ischaemia and reperfusion in STEMI and cardiac arrest.
We have a lot of high-tech, sophisticated and expensive in-hospital treatments today that we use every day. We must continue to do so, but we should also acknowledge the importance of the pre-hospital management of our patients and recognize the potential benefits of improvements in laypeople's information awareness and their contributions alongside pre-hospital emergency medical systems. Losing patients due to poor pre-hospital logistics is unacceptable in 2016, and new treatment algorithms should be evaluated in randomized trials whenever possible. The current post-resuscitation guidelines provide a common approach to managing the sickest of cardiac patients, but even guidelines must be challenged when appropriate. Both PCI and TTM need further documentation through good-quality clinical trials in the vulnerable OHCA patient population.
